

| | | | | | |
|--|---|----|---|---|--|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | <i>Complete if Known</i> Application Number 10/573,516 Filing Date March 27, 2006 First Named Inventor Daniel Bur et al. Art Unit 1625 Examiner Name John Mabry | |
| Sheet | 1 | of | 2 | Attorney Docket No: AC-43-US | |

| US PATENT DOCUMENTS | | | | | |
|---------------------|---------|-----------------|------------------|---|----------------------------|
| Examiner Initial * | Cite No | Document Number | Publication Date | Name of Patentee or Applicant of Cited Document | Filing Date If Appropriate |

| FOREIGN PATENT DOCUMENTS | | | | | |
|--------------------------|---------|-------------------------|------------------|---|----------------|
| Examiner Initials* | Cite No | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of cited Document | T ² |
| | | WO 99/40192 | 08-12-1999 | | |

| OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS | | | | |
|--|----------------------|---|----------------|--|
| Examiner Initials* | Cite No ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² | |
| | | AMES, R.S. et al., "Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14" Nature (1999), 401, pp. 282-286. | | |
| | | BERN, H.A. et al., "Neurohormones from fish tails: the caudal neurosecretory system. I. Urophysiology and the caudal neurosecretory system of fishes", Recent Prog. Horm. Res., (1985), 41, pp. 533-552. | | |
| | | BREU, V. et al., In vitro characterization of Ro-46-2005, a novel synthetic non-peptide antagonist of ET _A and ET _B receptors., FEBS Lett., (1993), 334, pp. 210-214. | | |
| | | CHEUNG, B.M. et al., "Plasma concentration of urotensin II is raised in hypertension", J. Hypertens., (2004), 22, pp. 1341-1344. | | |
| | | CLOZEL, M. et al., "Pharmacology of the Urotensin-II Receptor Antagonist ACT-058362: First Demonstration of a Pathophysiological Role of the Urotensin System", J. Pharmacol. Exp. Ther., (2004), 311, pp. 204-212. | | |
| | | DOUGLAS, S.A., et al., "Differential vasoconstrictor activity of human urotensin-II in vascular tissue isolated from the rat, mouse, dog, pig, marmoset and cynomolgus monkey", Br. J. Pharmacol., (2000), 131, pp. 1262-1274. | | |
| | | DOUGLAS, S.A. et al., "Human urotensin-II is a potent vasoactive peptide: pharmacological characterization in the rat, mouse, dog and primate", J. Cardiovasc. Pharmacol., (2000), 36, Suppl 1:S163-S166. | | |
| | | GARLTON, J., et al., "Central effects of urotensin-II following ICV administration in rats", Psychopharmacology (Berlin), (2001), 155, pp. 426-433. | | |
| | | HELLER, J. et al., "Increased urotensin II plasma levels in patients with cirrhosis and portal hypertension", J. Hepatol., (2002), 37, pp. 767-772. | | |
| | | LIU, Q. et al., "Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14", Biochem. Biophys. Res. Commun., (1999), 266, pp. 174-178. | | |
| | | MALINOWSKI, M., et al., "A Convenient Preparation of 4-Pyridinamine Derivatives", J. Prakt. Chem., (1988), 330, pp. 154-158. | | |

EXAMINER

DATE CONSIDERED

| | | | | | | | | | | | | | | | |
|--|-------------------|----|---|--|--|---------------------------|------------|--------------------|----------------|-----------------------------|-------------------|-----------------|------|----------------------|------------|
| Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | <div style="text-align: right; font-size: small;">Complete if Known</div> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/573,516</td> </tr> <tr> <td>Filing Date</td> <td>March 27, 2006</td> </tr> <tr> <td>First Named Inventor</td> <td>Daniel Bur et al.</td> </tr> <tr> <td>Art Unit</td> <td>1625</td> </tr> <tr> <td>Examiner Name</td> <td>John Mabry</td> </tr> </table> | | Application Number | 10/573,516 | Filing Date | March 27, 2006 | First Named Inventor | Daniel Bur et al. | Art Unit | 1625 | Examiner Name | John Mabry |
| Application Number | 10/573,516 | | | | | | | | | | | | | | |
| Filing Date | March 27, 2006 | | | | | | | | | | | | | | |
| First Named Inventor | Daniel Bur et al. | | | | | | | | | | | | | | |
| Art Unit | 1625 | | | | | | | | | | | | | | |
| Examiner Name | John Mabry | | | | | | | | | | | | | | |
| Sheet | 2 | of | 2 | Attorney Docket No: AC-43-US | | | | | | | | | | | |

| | | | |
|--|--|---|--|
| | | MORI, M. et al., "Urotensin II is the endogenous ligand of a G-protein-coupled orphan receptor, SENR (GPR14)", Biochem. Biophys. Res. Commun., (1999), 265, pp.123-129. | |
| | | "Protective Groups in Organic Synthesis", T.W. Greene, P.G.M. Wuts, Wiley-Interscience, (1999) | |
| | | RUSSELL, F.D., et al., "Cardiostimulant effects of urotensin-II in human heart in vitro", Br. J. Pharmacol., (2001), 132, pp. 5-9. | |
| | | SHENOUDA, S. et al., "Localization of urotensin-II immunoreactivity in normal human kidneys and renal carcinoma", J. Histochem. Cytochem., (2002), 50, pp. 885-889. | |
| | | SILVESTRE, R.A., et al., "Inhibition of insulin release by urotensin II-a study on the perfused rat pancreas", Horm Metab Res., (2001), 33, pp. 379-381. | |
| | | TAKAHASHI, K. et al., "Expression of utotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity b SW-13 adrenocortical carcinoma cells", Peptides, (2001), 22, pp. 1175-1179. | |
| | | TAKAHASHI, K. et al., "Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II", Peptides, (2003), 24, pp. 301-306. | |
| | | TOTSUNE, K. et al., "Role of urotensin II in patients on dialysis", Lancet, (2001), 358, pp. 810-811. | |
| | | TOTSUNE, K. et al., "Increased plasma urotensin II levels in patients with diabetes mellitus" Clin. Sci., (2003), 104, pp. 1-5. | |
| | | TSANDIS, A. et al., "Urotensin II stimulates collagen synthesis of cardiac fibroblasts and hypertrophic signaling in cardiomyocytes via G(alpha)q- and Ras-dependent pathways", J. Am. Coll. Cardiol., (2001), 37, p. 164A. | |
| | | ZOU, Y. et al., "Urotensin II induces hypertrophic responses in cultured cardiomyocytes from neonatal rats" FEBS Lett., (2001), 508, pp. 57-60. | |

EXAMINER

DATE CONSIDERED